Grant: Engage Grants Program
Institut national de la recherche scientifique
$24,850.00
Development of solid-support-bound oligonucleotides for the depletion of any ribosomal RNAs
FY 2012-13
Summary
DNA oligonucleotides are now a common commodity which is absolutely essential to research in life sciences.
In addition to standard DNA, customized oligonucleotides can now be synthesized with a large number of
chemical modifications. These modifications add new functional compounds on the DNA, e.g. fluorescence,
RNA polymers, nucleoside analogs or biotin. Biotin is typically used to attach the oligonucleotides to
streptavidin beads or other matrix for numerous applications, but it is very expensive and is perishable. To
achieve the applications, without the inconvenience of biotin-streptavidin, some oligonucleotide-synthesis
companies look for other avenues, such as controlled-pore-glass (CPG) beads with uncleavable-DNA.
Biocorp DNA Inc., a Montreal-based company that synthesizes oligonucleotides, has the capability to
synthesize a wide array of oligonucleotides with chemical modifications. In particular, this company is able to
synthesize oligonucleotides that would remain attached to the CPG beads after the synthesis. These novel
CPG-DNAs would advantageously substitute biotinylated-DNAs bound on streptavidin beads in terms of
efficiency of use and cost. While Biocorp DNA Inc. has all the equipment and expertise necessary to make the
new CPG-DNAs, it lacks the capacity to validate the result of the synthesis procedure fine-tuning as well as the
biochemical integrity of the CPG-DNAs and prove their efficiency in the targeted applications. Dr. Jonathan
Perreault's research group has all the required infrastructures and expertise to develop procedures required to
perform the validation of the CPG-DNA, which will be necessary before the CPG-DNAs can be sold. Once the
CPG-DNA is shown to work in standard biochemical/molecular biology procedures, Biocorp DNA Inc. will be
able to sell it as an attractive product for numerous laboratories and will have a promising market in various
fields using rRNA depletion, RNA enrichment or immobilized DNA such as high-throughput sequencing and
""pull-down based"" techniques.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
445830-2012
Name nom
Perreault, Jonathan
Department département
INRS-Institut Armand-Frappier
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
24850
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5402
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Nucleic acids
Research subject fr
Acides nucléiques
Partie
1
Nb partie
1
Application title
Development of solid-support-bound oligonucleotides for the depletion of any ribosomal RNAs
Keyword
NSERC
Application summary
DNA oligonucleotides are now a common commodity which is absolutely essential to research in life sciences.
In addition to standard DNA, customized oligonucleotides can now be synthesized with a large number of
chemical modifications. These modifications add new functional compounds on the DNA, e.g. fluorescence,
RNA polymers, nucleoside analogs or biotin. Biotin is typically used to attach the oligonucleotides to
streptavidin beads or other matrix for numerous applications, but it is very expensive and is perishable. To
achieve the applications, without the inconvenience of biotin-streptavidin, some oligonucleotide-synthesis
companies look for other avenues, such as controlled-pore-glass (CPG) beads with uncleavable-DNA.
Biocorp DNA Inc., a Montreal-based company that synthesizes oligonucleotides, has the capability to
synthesize a wide array of oligonucleotides with chemical modifications. In particular, this company is able to
synthesize oligonucleotides that would remain attached to the CPG beads after the synthesis. These novel
CPG-DNAs would advantageously substitute biotinylated-DNAs bound on streptavidin beads in terms of
efficiency of use and cost. While Biocorp DNA Inc. has all the equipment and expertise necessary to make the
new CPG-DNAs, it lacks the capacity to validate the result of the synthesis procedure fine-tuning as well as the
biochemical integrity of the CPG-DNAs and prove their efficiency in the targeted applications. Dr. Jonathan
Perreault's research group has all the required infrastructures and expertise to develop procedures required to
perform the validation of the CPG-DNA, which will be necessary before the CPG-DNAs can be sold. Once the
CPG-DNA is shown to work in standard biochemical/molecular biology procedures, Biocorp DNA Inc. will be
able to sell it as an attractive product for numerous laboratories and will have a promising market in various
fields using rRNA depletion, RNA enrichment or immobilized DNA such as high-throughput sequencing and
""pull-down based"" techniques.